SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ANKYLOSING SPONDYLITIS THROUGH 3 YEARS: LONG-TERM RESULTS OF TWO RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDIES

被引：0
|
作者：
Kvien, T. K. [1 ]
Deodhar, A. [2 ]
Gossec, L. [3 ]
Conaghan, P. G. [4 ]
Strand, V. [5 ]
Ostergaard, M. [6 ]
Williams, N. [7 ]
Porter, B. [8 ]
Gandhi, K. [8 ]
Jugl, S. [9 ]
机构：
[1] Diakonhjemmet Hosp, Oslo, Norway
[2] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[3] UPMC Univ Paris 06, Paris, France
[4] Univ Leeds, Leeds, W Yorkshire, England
[5] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA
[6] Copenhagen Ctr Arthrit Res COPECARE, Glostrup, Denmark
[7] RTI Hlth Solut, Durham, NC USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
[9] Novartis Pharma AG, Basel, Switzerland
来源：
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY | 2018年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
363
引用
收藏
页码：S9 / S9
页数：1
相关论文
共 50 条
  • [21] Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
    Gil Yosipovitch
    Nicholas Mollanazar
    Sonja Ständer
    Shawn G. Kwatra
    Brian S. Kim
    Elizabeth Laws
    Leda P. Mannent
    Nikhil Amin
    Bolanle Akinlade
    Heribert W. Staudinger
    Naimish Patel
    George D. Yancopoulos
    David M. Weinreich
    Sheldon Wang
    Genming Shi
    Ashish Bansal
    John T. O’Malley
    Nature Medicine, 2023, 29 : 1180 - 1190
  • [22] Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials
    Yosipovitch, Gil
    Mollanazar, Nicholas
    Staender, Sonja
    Kwatra, Shawn G.
    Kim, Brian S.
    Laws, Elizabeth
    Mannent, Leda P.
    Amin, Nikhil
    Akinlade, Bolanle
    Staudinger, Heribert W.
    Patel, Naimish
    Yancopoulos, George D.
    Weinreich, David M.
    Wang, Sheldon
    Shi, Genming
    Bansal, Ashish
    O'Malley, John T.
    NATURE MEDICINE, 2023, 29 (05) : 1180 - +
  • [23] SARILUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS: RESULTS OF A PHASE 2, RANDOMIZED. DOUBLE-BLIND, PLACEBO-CONTROLLED, INTERNATIONAL STUDY (ALIGN)
    Sieper, J.
    Inman, R. D.
    Badalamenti, S.
    Radin, A.
    Braun, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 111 - 112
  • [24] A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of Tildrakizumab Efficacy and Safety in Patients With Active Ankylosing Spondylitis
    Peters, Eric
    Chou, Richard C.
    Rozzo, Stephen J.
    Yao, Siu-Long
    Fructuoso, Ferran Jose Garcia
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 (05) : 223 - 229
  • [25] SECUKINUMAB PROVIDES SUSTAINED REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS THROUGH 3 YEARS: LONG-TERM DATA FROM THE FUTURE 1 AND FUTURE 2 STUDIES
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Gladman, D.
    Mease, P.
    Rasouliyan, L.
    Pricop, L.
    Gaillez, C.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 949 - 949
  • [26] Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
    Braun, Juergen
    Deodhar, Atul A.
    Sieper, Joachim
    Dougados, Maxime
    Porter, Brian
    Andersson, Mats
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [27] Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
    Sieper, Joachim
    Braun, Juergen
    Kay, Jonathan
    Badalamenti, Salvatore
    Radin, Allen R.
    Jiao, Lixia
    Fiore, Stefano
    Momtahen, Tanya
    Yancopoulos, George D.
    Stahl, Neil
    Inman, Robert D.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) : 1051 - 1057
  • [28] SECUKINUMAB EFFICACY IN ANTI-TNF-NAIVE PATIENTS AND PATIENTS PREVIOUSLY EXPOSED TO ANTI-TNF THERAPY: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY (MEASURE 2) IN ACTIVE ANKYLOSING SPONDYLITIS
    Sieper, J.
    Braun, J.
    Baraliakos, X.
    Baeten, D. L.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Porter, B.
    Andersson, M.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 272 - 272
  • [29] Efficacy of Fremanezumab Treatment in Patients ≥60 Years of Age With Episodic or Chronic Migraine: Pooled Results of 3 Randomized, Double-Blind, Placebo-controlled Phase 3 Studies
    Nahas, S. J.
    Ning, X.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V
    Silberstein, S. D.
    HEADACHE, 2020, 60 : 14 - 15
  • [30] SECUKINUMAB PROVIDES RAPID AND SUSTAINED REDUCTIONS IN DACTYLITIS AND ENTHESITIS IN PATIENTS WITH PSORIATIC ARTHRITIS: ANALYSIS OF DATA FROM THE PHASE 3 RANDOMIZED, MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED FUTURE 2 STUDY
    Kirkham, Bruce
    Mease, Philip J.
    McInnes, Iain B.
    RHEUMATOLOGY, 2017, 56 : 77 - 77
12345